Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 942189-39-1 | MDL No. : | MFCD17169854 |
Formula : | C26H18BrN3O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PDUHZXZECHMGLL-UHFFFAOYSA-N |
M.W : | 484.34 g/mol | Pubchem ID : | 58946443 |
Synonyms : |
|
Num. heavy atoms : | 32 |
Num. arom. heavy atoms : | 27 |
Fraction Csp3 : | 0.04 |
Num. rotatable bonds : | 5 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 130.86 |
TPSA : | 63.64 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -4.14 cm/s |
Log Po/w (iLOGP) : | 3.62 |
Log Po/w (XLOGP3) : | 7.2 |
Log Po/w (WLOGP) : | 6.55 |
Log Po/w (MLOGP) : | 5.81 |
Log Po/w (SILICOS-IT) : | 3.82 |
Consensus Log Po/w : | 5.4 |
Lipinski : | 1.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 1.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -7.67 |
Solubility : | 0.0000103 mg/ml ; 0.0000000212 mol/l |
Class : | Poorly soluble |
Log S (Ali) : | -8.36 |
Solubility : | 0.00000212 mg/ml ; 0.0000000044 mol/l |
Class : | Poorly soluble |
Log S (SILICOS-IT) : | -9.76 |
Solubility : | 0.0000000851 mg/ml ; 0.0000000002 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 2.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 3.54 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H320-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
10% | Stage #1: With bromine In methanol Stage #2: With sodium hydride In N,N-dimethyl-formamide |
(S)-N-(3-(6-isopropoxypyridin-3-yl)- 1H-indazol-5-yl)- 1 -(2-(4-(4-(1 -methyl-1H- 1 ,2,4-triazol-3 -yl)phenyl)-3 , 6-dihydropyridin- 1 (2H)-yl)-2-oxoethyl)-3 -(methylthio)pyrrolidine3-carboxamide free base synthesis is a 19 step process. Compound preparation is divided into three intermediate preparations A, B and C followed by coupling of the intermediates. Allintermediates start with commercially available compounds. Compound 5 is prepared by reaction of the commercially available bromo-4-cyanobenzene with methyl hydrazine under acidic conditions to form the hydrazinoimidate 2 in modest yield. After reaction with formic acid in two steps the bromophenyl-N-methyl triazole intermediate 3 is obtained. The tetrahydropyridine ring is introduced by a Suzuki reaction of the commercially available Bocprotected tetrahydropyridine-boronate to obtain the tricyclic ring system 4. Chloroacetamide 5 is obtained in excellent yield by reaction of the deprotected 4 with chloroacetylchloride. The pyrrolidine core lOa is obtained in good yield in 5 steps starting from commercially available 6. Reaction with thionylchloride gave the thiomethyl olefin 7. Cycloaddition (2+3) gives 8 followed by removal of the benzyl protection group to give 9. L-Tartaric acid resolution of thepyrrolidine core gives the pure (5) enantiomer 9 after filtration from methanol. After protection as the Boc derivative and hydrolysis of the methyl ester, 10 is obtained in overall 50percent yield. Compound 17 is obtained from commercially available indazole 11. Bromination at the 3- position of indazole 11 proceeds in excellent yield without chromatography to obtain 12. Suzuki reaction of the bromo compound 12 with 14 gives the nitro indazole 16 after chromatography.Reduction of 16 gives aniline 17 as an oil in quantitative yield without chromatography. The final coupling of the intermediates proceeded by coupling 17 with lOa to obtain 18 in good yield. After deprotection of the Boc and Trityl groups the final coupling with 5 gave (S)-N-(3-(6- isopropoxypyridin-3-yl)- 1H-indazol-5-yl)-1 -(2-(4-(4-(1 -methyl-1H- 1 ,2,4-triazol-3-yl)phenyl)- 3 ,6-dihydropyridin- 1 (2H)-yl)-2-oxoethyl)-3 -(methylthio)pyrrolidine-3 -carboxamide afterchromatography. Final purification is carried out by crystallization from methanol/diethylether.This synthetic route has been conducted on a scale that delivered (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)- 1 -(2-(4-(4-(1 -methyl-1H- 1 ,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1 (2H)-yl)-2-oxoethyl)-3 -(methylthio)pyrroli dine-3 -carboxamide free base (Compound I). |
[ 529508-58-5 ]
1-(3-Fluorobenzyl)-5-nitro-1H-indazole
Similarity: 0.66
[ 1785580-89-3 ]
3-Bromo-1-methyl-5-phenyl-1H-pyrazole
Similarity: 0.64
[ 1204355-48-5 ]
1-(tert-Butyl)-5-phenyl-1H-pyrazole
Similarity: 0.63
[ 1700661-39-7 ]
3-Bromo-4-methyl-1-phenyl-1H-pyrazole
Similarity: 0.62
[ 74209-25-9 ]
3-Bromo-1-methyl-5-nitro-1H-indazole
Similarity: 0.77
[ 1092351-49-9 ]
3-Bromo-1-methyl-1H-indazol-5-amine
Similarity: 0.68
[ 74209-25-9 ]
3-Bromo-1-methyl-5-nitro-1H-indazole
Similarity: 0.77
[ 74209-25-9 ]
3-Bromo-1-methyl-5-nitro-1H-indazole
Similarity: 0.77